Improving Data Collection in Pregnancy Safety Studies: Towards Standardisation of Data Elements in Pregnancy Reports from Public and Private Partners, A Contribution from the ConcePTION Project

Guillaume Favre, Jonathan L. Richardson, Alan Moore, Yvonne Geissbühler, Valentine Jehl, Alison Oliver, Svetlana Shechtman, Orna Diav-Citrin, Maya Berlin, Tal Haan, David Baud, Alice Panchaud, Anil Mor, Meritxell Sabidó, Sabrina Souza, Christina Chambers, Yrea R. J. Rijt-Weetink, Eugène P. Puijenbroek, Laura M. Yates, François Girardin, Michael Stellfeld and Ursula Winterfeld ()
Additional contact information
Guillaume Favre: Lausanne University Hospital and University of Lausanne
Jonathan L. Richardson: Newcastle upon Tyne Hospitals NHS Foundation Trust
Alan Moore: Novartis Pharma AG
Yvonne Geissbühler: Novartis Pharma AG
Valentine Jehl: Novartis Pharma AG
Alison Oliver: Newcastle upon Tyne Hospitals NHS Foundation Trust
Svetlana Shechtman: Ministry of Health
Orna Diav-Citrin: Ministry of Health
Maya Berlin: Zerifin TIS, Tel Aviv University
Tal Haan: Zerifin TIS, Tel Aviv University
David Baud: Lausanne University Hospital and University of Lausanne
Alice Panchaud: University of Bern
Anil Mor: Sanofi
Meritxell Sabidó: Merck Healthcare KGaA
Sabrina Souza: Merck Healthcare KGaA
Christina Chambers: University of California San Diego
Yrea R. J. Rijt-Weetink: Pharmacovigilance Centre Lareb
Eugène P. Puijenbroek: Pharmacovigilance Centre Lareb
Laura M. Yates: Newcastle upon Tyne Hospitals NHS Foundation Trust
François Girardin: Lausanne University Hospital and University of Lausanne
Michael Stellfeld: Novo Nordisk A/S
Ursula Winterfeld: Lausanne University Hospital and University of Lausanne

Drug Safety, 2024, vol. 47, issue 3, No 4, 227-236

Abstract: Abstract Introduction and Objective The ConcePTION project aims to improve the way medication use during pregnancy is studied. This includes exploring the possibility of developing a distributed data processing and analysis infrastructure using a common data model that could form a foundational platform for future surveillance and research. A prerequisite would be that data from various data access providers (DAPs) can be harmonised according to an agreed set of standard rules concerning the structure and content of the data. To do so, a reference framework of core data elements (CDEs) recommended for primary data studies on drug safety during pregnancy was previously developed. The aim of this study was to assess the ability of several public and private DAPs using different primary data sources focusing on multiple sclerosis, as a pilot, to map their respective data variables and definitions with the CDE recommendations framework. Methods Four pregnancy registries (Gilenya, Novartis; Aubagio, Sanofi; the Organization of Teratology Information Specialists [OTIS]; Aubagio, Sanofi; the Dutch Pregnancy Drug Register, Lareb), two enhanced pharmacovigilance programmes (Gilenya PRIM, Novartis; MAPLE-MS, Merck Healthcare KGaA) and four Teratology Information Services (UK TIS, Jerusalem TIS, Zerifin TIS, Swiss TIS) participated in the study. The ConcePTION primary data source CDE includes 51 items covering administrative functions, the description of pregnancy, maternal medical history, maternal illnesses arising in pregnancy, delivery details, and pregnancy and infant outcomes. For each variable in the CDE, the DAPs identified whether their variables were: identical to the one mentioned in the CDE; derived; similar but with a divergent definition; or not available. Results The majority of the DAP data variables were either directly taken (85%, n = 305/357, range 73–94% between DAPs) or derived by combining different variables (12%, n = 42/357, range 0–24% between DAPs) to conform to the CDE variables and definitions. For very few of the DAP variables, alignment with the CDE items was not possible, either because of divergent definitions (1%, n = 3/357, range 0–2% between DAPs) or because the variables were not available (2%, n = 7/357, range 0–4% between DAPs). Conclusions Data access providers participating in this study presented a very high proportion of variables matching the CDE items, indicating that alignment of definitions and harmonisation of data analysis by different stakeholders to accelerate and strengthen pregnancy pharmacovigilance safety data analyses could be feasible.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-023-01384-3 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:47:y:2024:i:3:d:10.1007_s40264-023-01384-3

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-023-01384-3

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().